Nilotinib hydrochloride is a potent tyrosine kinase inhibitor used primarily for the treatment of Philadelphia chromosome-positive chronic myelogenous leukaemia. By selectively inhibiting the BCR-ABL fusion… Read more
Nilotinib hydrochloride is a potent tyrosine kinase inhibitor used primarily for the treatment of Philadelphia chromosome-positive chronic myelogenous leukaemia. By selectively inhibiting the BCR-ABL fusion protein, this therapeutic agent helps manage chronic or accelerated phase disease in adult patients. To ensure the safety and efficacy of this active pharmaceutical ingredient, rigorous analytical testing is required throughout the drug development and manufacturing lifecycle. The reference standards, including non-pharmacopeial impurities, metabolites, and stable isotope-labelled compounds available in this category, are essential tools for pharmaceutical laboratories. These materials facilitate precise impurity profiling, method validation, and consistent quality control, allowing analytical chemists to accurately quantify trace levels of related substances and support regulatory compliance for this oncological medication.